Eli Lilly and - LLY Stock Forecast, Price & News

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on LLY shares. Mizuho raised their price target on Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. Morgan Stanley raised their price target on Eli Lilly and from $369.00 to $395.00 and gave the stock an "overweight" rating in a research note on Friday, July 8th. UBS Group raised their price target on Eli Lilly and to $335.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 27th. JPMorgan Chase & Co. lifted their target price on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Finally, Barclays lifted their target price on Eli Lilly and from $333.00 to $355.00 and gave the company an "overweight" rating in a research report on Thursday, July 7th. Three analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $317.00.

Eli Lilly and Stock Up 2.3 %

Shares of LLY traded up $6.91 during trading hours on Friday, hitting $308.08. The company had a trading volume of 2,303,399 shares, compared to its average volume of 2,908,082. Eli Lilly and has a one year low of $220.20 and a one year high of $335.33. The company's fifty day moving average price is $315.32 and its two-hundred day moving average price is $290.68. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70. The company has a market capitalization of $292.73 billion, a PE ratio of 48.57, a price-to-earnings-growth ratio of 2.08 and a beta of 0.35.

Eli Lilly and (NYSE:LLY - Get Rating) last announced its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The business had revenue of $6.49 billion for the quarter, compared to analysts' expectations of $6.85 billion. During the same quarter last year, the firm earned $1.87 earnings per share. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. As a group, equities analysts forecast that Eli Lilly and will post 7.96 earnings per share for the current fiscal year.

Eli Lilly and Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be paid a dividend of $0.98 per share. The ex-dividend date of this dividend is Friday, August 12th. This represents a $3.92 annualized dividend and a yield of 1.27%. Eli Lilly and's dividend payout ratio (DPR) is 62.52%.

Insider Buying and Selling

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 700 shares of the business's stock in a transaction dated Wednesday, May 18th. The stock was sold at an average price of $302.00, for a total transaction of $211,400.00. Following the sale, the insider now owns 105,472,666 shares in the company, valued at approximately $31,852,745,132. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Eli Lilly and news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Wednesday, June 1st. The stock was sold at an average price of $313.44, for a total transaction of $313,440.00. Following the sale, the chief accounting officer now owns 6,274 shares in the company, valued at approximately $1,966,522.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 700 shares of the business's stock in a transaction dated Wednesday, May 18th. The shares were sold at an average price of $302.00, for a total value of $211,400.00. Following the sale, the insider now owns 105,472,666 shares in the company, valued at approximately $31,852,745,132. The disclosure for this sale can be found here. Insiders have sold a total of 1,196,052 shares of company stock worth $380,334,353 in the last ninety days. 0.12% of the stock is owned by insiders.